Table 1.
List of specimens.
Characteristics of HMEC strains and uncultured organoids
| Sample | Age (years) | Source | Country of surgery | Est prestasis strain | Organoid analysis | Known characteristics/pathology notes |
|---|---|---|---|---|---|---|
| 48R | 16 | RM | USA | yes | African American | |
|
| ||||||
| 160 | 16 | RM | USA | yes | ||
|
| ||||||
| 240 | 19 | RM | USA | yes | mildly hyperplastic | |
|
| ||||||
| 404 | 19 | RM | USA | no | CD10, CD227, CD49f | minimal fibrocystic change |
|
| ||||||
| 407P | 19 | P | USA | yes | IDC, lymphnode+, ER+, PR+ | |
|
| ||||||
| 168R | 19 | RM | USA | yes | African American | |
|
| ||||||
| D1 | 19 | RM | DK | no | cKit | |
|
| ||||||
| 399 | 20 | RM | USA | yes | benign | |
|
| ||||||
| 356 | 21 | RM | USA | yes | CD10, CD227, CD49f | normal |
|
| ||||||
| 184 | 21 | RM | USA | yes | ||
|
| ||||||
| 1P | 24 | P | USA | yes | IDC, lymphnode- | |
|
| ||||||
| 97 | 27 | RM | USA | yes | ||
|
| ||||||
| 195L | 27 | RM | USA | yes | CD10, CD227, CD49f | |
|
| ||||||
| 123 | 27 | RM | USA | yes | African American, mammary hyperplasis | |
|
| ||||||
| 400 | 27 | RM | USA | no | CD10, CD227, CD49f | mild ductal ectsia and mastitis |
|
| ||||||
| 51L | 28 | RM | USA | yes | mild periductal mastitis (R+L), focal microcalcification (R.) | |
|
| ||||||
| 172L | 28 | RM | USA | yes | minimal phase of fibrocystic disease | |
|
| ||||||
| D2 | 28 | RM | DK | no | cKit | |
|
| ||||||
| 124 | 29 | RM | USA | yes | ||
|
| ||||||
| 676P | 29 | P | USA | yes | ||
|
| ||||||
| 42P | 30 | P | USA | yes | IDC, lymphnode- | |
|
| ||||||
| 1030P | 30 | P | USA | yes | ||
|
| ||||||
| D2 | 30 | RM | DK | no | cKit | |
|
| ||||||
| D4 | 32 | RM | DK | no | cKit | |
|
| ||||||
| D5 | 33 | RM | DK | no | cKit | |
|
| ||||||
| D6 | 34 | RM | DK | no | cKit | |
|
| ||||||
| 90P | 36 | P | USA | yes | BRCA1 mut (185delAG) | |
|
| ||||||
| D7 | 37 | RM | DK | no | cKit | |
|
| ||||||
| 100P | 39 | P | USA | yes | non-invasive ductal carcinoma, ER−, PR− | |
|
| ||||||
| D8 | 41 | RM | DK | no | cKit | |
|
| ||||||
| 245AT | 41 | RM | USA | yes | ATM heterozyote, tissue was clinically normal tissue | |
|
| ||||||
| D9 | 44 | RM | DK | no | cKit | |
|
| ||||||
| D10 | 44 | RM | DK | no | cKit | |
|
| ||||||
| 173P | 45 | RM | USA | yes | IDC, ER−, PR− | |
|
| ||||||
| D11 | 54 | RM | DK | no | cKit | |
|
| ||||||
| 191 | 56 | RM | USA | yes | slight fibrocystic disease, hypertrophy, stromal fibrosis and adenosis present in mammary parenchyma | |
|
| ||||||
| 117 | 56 | RM | USA | yes | patchy stromal fibrosis (R.), fibrocystic disease (L.) | |
|
| ||||||
| 335P | 58 | P | USA | yes | Infiltrating adenocarcinoma, ER+, PR+/− | |
|
| ||||||
| 153L | 60 | RM | USA | yes | benign fibrocystic disease | |
|
| ||||||
| 639P | 60 | P | USA | yes | ||
|
| ||||||
| 122L | 62 | RM | USA | yes | fibrocystic disease, hypertrophy, apocrine metaplasia of ductal epithelium, cystic dilatia of ducts and focal areas of intraductal hyperplasia | |
|
| ||||||
| 394P | 64 | P | USA | no | CD10, CD227, CD49fIDC | |
|
| ||||||
| 881P | 65 | P | USA | yes | ||
|
| ||||||
| 355P | 66 | P | USA | no | CD10, CD227, CD49f | Infiltrating adenocarcinoma |
|
| ||||||
| 374P | 66 | P | USA | no | CD10, CD227, CD49f | infiltrating adenocarcinoma, Padget disease |
|
| ||||||
| 96R | 66 | RM | USA | yes | slight focal fibrocystic change | |
|
| ||||||
| 429 | 72 | RM | USA | yes | ||
|
| ||||||
| 353P | 72 | P | USA | yes | Colloid (mucinous) carcinoma, ER+/−, PR− | |
|
| ||||||
| 464P | 80 | P | USA | yes | ||
|
| ||||||
| 451P | 83 | P | USA | yes | ||
|
| ||||||
| 805P | 91 | P | USA | yes | CD10, CD227, CD49f | |
Soure: RM = Reduction mammoplasty tissue, P = Peripheral non-tumor containing mastectomy tissue.
Country of surgery: USA = Peralta Cancer Center, Oakland CA USA; DK = University of Copenhagen, Copenhagen, Denmark
Organoid analysis: anti CD10 clone HI10a, anti CD227 #559774, anti CD49f clone GoH3, anti cKit clones 104D2 and K45.
Known characteristics/pathology notes: Information is incomplete, but was provided here cases in which some outstanding feature was known to the authors or was noted in pathology reports. (ER=estrogen receptor, PR=progesterone receptor, IDC=invasive ductal carcinoma.)